Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORMD-0801 Oral Insulin in Type 2 Diabetes – China Phase 3
CTR20201644Phase 3Completed
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ORMD-0801 in type 2 diabetes mellitus (T2DM), sponsored by Oramed Pharmaceuticals Inc.. Started Aug 2020; status: completed.
02
Drugs
ORMD-0801
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20201644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201644.